Health Trials

Clinical trials

2

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Phase I Trial of Memory T Cells Expressing an NKG2D Chimeric Antigen Receptor in Children, Adolescents and Young Adults With Advanced Sarcoma

Phase I, open label, prospective, single-center, non-randomized, dose escalation clinical trial aiming to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) of systemic transduced donor-derived NKG2D-CAR memory T cell infusions (Arm A), and of dual treatment, with both systemic and locally transduced donor-derived NKG2D-CAR memory T cell infusions (Arm B).

Participants needed: 18
Trial details
Phase: Phase 1Age: Up to 30Biological sex: AllType: InterventionalSponsor: Antonio Pérez MartínezUpdated: Apr 12, 2024Locations: 1
Eligibility criteria

Age: ≤ 40 years at the time of recurrence or progression with any type of sarcom... [+19]

Enrolled in another treatment protocol. [+9]

Read more
Status: Recruiting

Clinical Trial of Infusion of Activated NK Cells for the Treatment of Sarcomas

This is an exploratory therapeutic study (according to the terminology of the "ICH Harmonised Tripartite Guideline Topic E8. General Considerations for Clinical Trials". EMEA, March 1998. CPMP/ICH/291/95), open-label, non-randomized, multicenter study. It is considered phase I/II since the safety and efficacy of the infusion of allogeneic haploidentical NK cells in combination with chemotherapy and/or radiotherapy in the treatment of pediatric, adolescent and young adult patients with refractory sarcoma will be sought.

Participants needed: 10
Trial details
Age: Up to 30Biological sex: AllType: InterventionalSponsor: Antonio Pérez MartínezUpdated: Jul 21, 2023Locations: 1
Eligibility criteria

Patients aged between 0 and 30 years diagnosed with malignant sarcoma, who at th... [+8]

Patients with a history of poor therapeutic compliance. [+8]

Read more